Sugarman Jeremy
Department of Medicine, Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD 21205, USA.
Prog Cardiovasc Dis. 2007 Jul-Aug;50(1):1-6. doi: 10.1016/j.pcad.2007.02.003.
As research on stem cell therapeutics for the treatment of cardiovascular diseases in adults is being planned and conducted it is essential to address the ethical issues associated with it. The considerable attention that is currently focused on the ethical issues associated with stem cell research as well as the acute clinical situations sometimes encountered when treating cardiovascular disease, underscore the need for explicit attention to the ethical aspects of this research. In this article, I survey some of the key ethical considerations regarding research involving stem cell therapeutics for cardiovascular diseases including: (1) the standard ethical considerations for translational and clinical research and mechanisms of ethical oversight of them; (2) additional oversight related to stem cell research; (3) considerations for obtaining informed consent for this research and in selecting individual human subjects to participate in it; (4) concerns related to justice that may manifest themselves with respect to which research endeavors move forward and (5) conflicts of interest in research and their potential relationship to research integrity.
随着针对成人心血管疾病的干细胞治疗研究正在规划和开展,解决与之相关的伦理问题至关重要。当前对干细胞研究相关伦理问题的高度关注,以及在治疗心血管疾病时有时会遇到的紧急临床情况,凸显了明确关注这项研究伦理方面的必要性。在本文中,我探讨了一些关于心血管疾病干细胞治疗研究的关键伦理考量,包括:(1)转化研究和临床研究的标准伦理考量及其伦理监督机制;(2)与干细胞研究相关的额外监督;(3)为这项研究获取知情同意以及选择个体人类受试者参与研究的考量;(4)在哪些研究项目能够推进方面可能出现的与公正相关的问题;以及(5)研究中的利益冲突及其与研究诚信的潜在关系。